Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu

Clinical Trials and Research

Clinical Trials

Our program is currently participating in several exciting clinical trials to investigate new drugs or new drug indications for pulmonary hypertension.

Open Trials

PERFECT (Phase 3) - Open to enrollment

Assess the safety and efficacy of Inhaled Treprostinil in COPD-PH.

ROR-PH-301 (Phase 3) - Open to enrollment

Assess safety and efficacy of ralinepag in combination with current standard of care medications in PAH.

ROR-PH-303 (Phase 3)

Open label extension to ROR-PH-301 to assess long term safety and efficacy of ralinepag in PAH.

CATALYST (Phase 3) - Open to enrollment

Assess safety and efficacy of bardoxolone methyl in connective tissue disease associated PAH.

RANGER (Phase 3a)

Open label extended access program for participants who have completed the CATALYST study to assess long-term safety of bardoxolone methyl.

PB1046-PT-CL-0004 (Phase 2) - Open to enrollment

Assess the safety, tolerability, efficacy of subcutaneous PB1046 (VIP analogue) in PAH.

PB1046-PT-CL-0006 (Phase 2)

Open label Long-term extension for participants who have completed PB1046-PT-CL-0004.

Closed Trials

REPLACE (Phase 4) - Closed to enrollment

Study of Riociguat with or without endothelin receptor antagonist in PAH.

TDE-PH-311 (Phase 3) - Closed to enrollment

Open label long term follow up of UT-15C (oral treprostinil) for participants who completed TDE-PH-310.

Clinical Research

We also participate in a variety of non-interventional, observational based research.

Open Studies

Pulmonary Hypertension Association Registry (PHAR) - Open to enrollment

Involves collection of information from patients with PH who are cared for at PHA Care Centers throughout the U.S. to track how patients with PH are evaluated, tested, and treated, and how well they do. The goal of the project is to see how care centers use recommended guidelines and see if there are certain factors which lead to better or worse outcomes in patients with PH.

Learn more at the Pulmonary Hypertension Association Registry (PHAR)

Extracellular Vesicles and Heart Rate monitoring as a Biomarker in Pulmonary Arterial Hypertension (POEM) - Open to enrollment

Involves collection of blood and heart rate data during exercise from patient with and without pulmonary disease to learn more about how current and future treatments influence certain blood components and exercise parameters.

Studies Enrolling Soon

ADAPT- open to enrollment soon

Observation based study to learn about real-world use and tolerability of Orenitram for the treatment of PAH.

Closed Studies

PAH Biobank - Closed to enrollment

Involves collection of blood samples and clinical data from patients with PAH to be made available upon request to scientists researching the disease. These efforts will help us learn about what genes might cause PAH, new markers and how to better treat the disease.

United States Pulmonary Hypertension Scientific Registry (USPHSR) - Closed to enrollment

Involves collection of information related to environmental exposures in PAH patients to develop a registry database to promote greater understanding of the disease in context of new genetic discoveries and treatments.